IMDX

Insight Molecular Diagnostics Inc. (IMDX)

$2.4

Last Close (24-hour delay)

PASS

• BUY Advisory
• SELL Advisory (Profit)​
• SELL Advisory (Loss)​

• Profit
• Loss
• Pass (Skip investing)

Stock price based on last close

*as per simulation
(see disclosures)

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock

Historic Profit -36.76%

Avg. Invested days 27

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance 2.0

Stock Returns Performance 1.0

Profits based on simulation

Last Close 08/14/2025

Upturn AI SWOT

Insight Molecular Diagnostics Inc.

Company Overview

History and Background

There is no publicly traded company with the name "Insight Molecular Diagnostics Inc." and therefore no historical data can be provided.

Core Business Areas

Leadership and Structure

Data unavailable for Insight Molecular Diagnostics Inc.

Top Products and Market Share

Key Offerings

Market Dynamics

Industry Overview

Data unavailable for Insight Molecular Diagnostics Inc.

Positioning

Data unavailable for Insight Molecular Diagnostics Inc.

Total Addressable Market (TAM)

Data unavailable for Insight Molecular Diagnostics Inc.

Upturn SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Competitors and Market Share

Key Competitors

Competitive Landscape

Data unavailable for Insight Molecular Diagnostics Inc.

Growth Trajectory and Initiatives

Historical Growth: Data unavailable for Insight Molecular Diagnostics Inc.

Future Projections: Data unavailable for Insight Molecular Diagnostics Inc.

Recent Initiatives: Data unavailable for Insight Molecular Diagnostics Inc.

Summary

Insufficient information is available to assess Insight Molecular Diagnostics Inc. The absence of a publicly traded entity with that name precludes a comprehensive evaluation. Without financial data or market presence, no statement can be made on the company's strengths, weaknesses, or outlook.

Peer Comparison

Sources and Disclaimers

Data Sources:

• Public search engines, Financial databases

Disclaimers:

Analysis is based on available public information. The lack of data for "Insight Molecular Diagnostics Inc." limits the scope and accuracy of the analysis. This analysis should not be used for investment decisions.

AI Summarization is directionally correct and might not be accurate.

Summarized information shown could be a few years old and not current.

Fundamental Rating based on AI could be based on old data.

AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Irvine, California.